Top Markets
#1 Black Phoenix Black Phoenix +734.39%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.97%
#3 MetaDAO MetaDAO +22.54%
#4 Wrapped STX (Velar) Wrapped STX (Velar) +18.17%
#5 Verus Coin Verus Coin +14.03%
#6 Akedo Akedo +8.97%
#7 Biconomy Biconomy +8.23%
#8 Tokamak Network Tokamak Network +7.07%
#9 XYO Network XYO Network +6.81%
#10 Tornado Cash Tornado Cash +5.67%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
UniQure N.V. UniQure N.V.

UniQure N.V.

QURE
Rank in Stocks #4592
uniQure N.V. develops treatments for patients suffering from rare and other... uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Share Price
$50.67
Last synced: 2026-08-26
Market Cap
$3.51B
Change (1 day)
-0.75%
Change (1 year)
221.68%
Country
NL
Trade UniQure N.V. (QURE)

Category

Healthcare
Operating Margin for UniQure N.V. (QURE)
Operating Margin as of 2026 TTM: 0.00%
According to UniQure N.V. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for UniQure N.V. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.